Alpha Lipoic Acid

Alpha-lipoic acid (ALA, also called thioctic acid) is a sulfur-containing compound studied across diabetic peripheral neuropathy (its primary established clinical application), inflammatory and antioxidant biomarkers, metabolic syndrome markers including glucose tolerance and lipid profiles, weight management, cognitive function, and several smaller research areas. The compound is synthesized in the mitochondria and obtained from dietary sources; it functions as both a fat-soluble and water-soluble antioxidant and is one of the few compounds that can regenerate other antioxidants (vitamin C, vitamin E, glutathione). The R-enantiomer is the biologically active form, though most consumer products contain a racemic R/S mixture.

The outcome dimensions covered most heavily are diabetic peripheral neuropathy (where ALA has been used in European clinical practice for decades, with extensive trial and meta-analytic coverage), inflammatory biomarkers including high-sensitivity C-reactive protein and oxidative stress markers, metabolic syndrome markers including fasting glucose and lipid profiles, weight management (smaller and more contested literature), and antioxidant effects in various clinical contexts. Newer research streams cover cognitive function in mild cognitive impairment, mitochondrial-disease contexts, and chemotherapy-induced peripheral neuropathy.

Demographically, the diabetic neuropathy literature concentrates on adults with type 2 diabetes and documented neuropathy; the metabolic-marker literature is broader across adults with metabolic risk factors. Form variability is a methodological complication: R-only ALA, racemic R/S-ALA, and sodium-R-lipoate (a more stable form) are not interchangeable across the literature, and bioavailability differences are well-documented. European clinical practice typically uses higher doses than US consumer supplementation, which is one of the differences between clinical-application and consumer-context research.